Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | LDHA | P00338 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347512 | 0.86 | EPHX2 (0.51) | ALDH1A1HTTKDM4EMEN1KMT2A | |
| SCHEMBL1346468 | 0.84 | TAS1R3 (0.47) | ALDH1A1HTTMEN1KMT2ANPC1 | |
| SCHEMBL1345038 | 0.81 | LDHA (0.42) | TAS2R14ALDH1A1HTTKDM4EMITF | |
| SCHEMBL15668966 | 0.80 | HTT (0.51) | ALDH1A1HTTKDM4EMITFLMNA | |
| SCHEMBL2048973 | 0.75 | LDHA (0.54) | ALDH1A1HTTKDM4EMITFLMNA | |
| SCHEMBL3264693 | 0.74 | PPARD (0.51) | TAS2R14HTTNPC1LMNAEPHX2 | |
| SCHEMBL11764494 | 0.73 | ALOX15 (0.51) | ALDH1A1KDM4EMEN1KMT2ANPC1 | |
| SCHEMBL1346881 | 0.73 | LMNA (0.76) | TAS2R14ALDH1A1HTTKMT2ANPC1 | |
| SCHEMBL1344851 | 0.72 | EPHX2 (0.53) | ALDH1A1HTTKDM4EMEN1KMT2A | |
| SCHEMBL3235287 | 0.72 | LDHA (0.44) | TAS2R14ALDH1A1HTTKDM4EMITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406206-B1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | MSD OSS BV (NL) | 2013-01-30 | — | — | EP | disclosed |
| US-8063102-B2 | Tetrahydronaphthalen-2-ol derivatives | N.V. ORGANON (NL) | 2011-11-22 | — | — | US | disclosed |
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | N. V. ORGANON | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240748-A1 | TETRAHYDRONAPHTHALEN-2-OL DERIVATIVES | VHL, BRCA1, TPH2 | TAS2R14 2449/4885ALDH1A1 286/4885HTT 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.